Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA; Globe Study Group. Lai CL, et al. Among authors: rasenack j. N Engl J Med. 2007 Dec 20;357(25):2576-88. doi: 10.1056/NEJMoa066422. N Engl J Med. 2007. PMID: 18094378 Free article. Clinical Trial.
Telbivudine improves renal function in patients with chronic hepatitis B.
Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A. Gane EJ, et al. Among authors: rasenack j. Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22. Gastroenterology. 2014. PMID: 24067879 Clinical Trial.
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O'Brien C, Nguyen TT, Jia J, Poynard T, Belanger B, Bao W, Naoumov NV. Zeuzem S, et al. Among authors: rasenack j. J Hepatol. 2009 Jul;51(1):11-20. doi: 10.1016/j.jhep.2008.12.019. Epub 2009 Feb 12. J Hepatol. 2009. PMID: 19345439 Clinical Trial.
Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Zeuzem S, et al. Among authors: rasenack j. N Engl J Med. 2000 Dec 7;343(23):1666-72. doi: 10.1056/NEJM200012073432301. N Engl J Med. 2000. PMID: 11106715 Free article. Clinical Trial.
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Zeuzem S, et al. Among authors: rasenack j. J Hepatol. 2003 Jul;39(1):106-11. doi: 10.1016/s0168-8278(03)00187-9. J Hepatol. 2003. PMID: 12821051 Clinical Trial.
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK. Foster GR, et al. Among authors: rasenack j. J Viral Hepat. 2013 Apr;20(4):e115-23. doi: 10.1111/jvh.12020. Epub 2013 Feb 14. J Viral Hepat. 2013. PMID: 23490379 Clinical Trial.
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team. Nelson DR, et al. Among authors: rasenack jw. Gastroenterology. 2010 Oct;139(4):1267-76. doi: 10.1053/j.gastro.2010.06.062. Epub 2010 Jul 1. Gastroenterology. 2010. PMID: 20600017 Free PMC article. Clinical Trial.
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV; VITAL-1 study team. Pawlotsky JM, et al. Among authors: rasenack j. Hepatology. 2015 Oct;62(4):1013-23. doi: 10.1002/hep.27960. Epub 2015 Aug 10. Hepatology. 2015. PMID: 26118427 Clinical Trial.
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; B2202 Study Team. Pianko S, et al. Among authors: rasenack j. J Viral Hepat. 2012 Sep;19(9):623-34. doi: 10.1111/j.1365-2893.2012.01586.x. Epub 2012 Mar 21. J Viral Hepat. 2012. PMID: 22863266 Clinical Trial.
75 results